Managing nirmatrelvir/ritonavir during COVID-19: pharmacists’ experiences from the Perak state of Malaysia

References

• Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature. 2022;608:603–608.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408.
   PubMed Web of Science ®Google Scholar
• Visacri MB, Figueiredo IV, Lima TdM. Role of pharmacist during the COVID-19 pandemic: a scoping review. Res Soc Adm Pharm. 2021;17(1):1799–1806.
   PubMed Web of Science ®Google Scholar
• Elbeddini A, Prabaharan T, Almasalkhi S, Tran C. Pharmacists and COVID-19. J Pharm Policy Pract. 2020;13(1):36.
   PubMed Web of Science ®Google Scholar
• Thong KS, Selvaratanam M, Tan CP, Cheah MF, Oh HL, Lee PM, et al. Pharmacy preparedness in handling COVID-19 pandemic: a sharing experience from a Malaysian tertiary hospital. J Pharm Policy Pract. 2021;14(1):61.
   PubMedGoogle Scholar
• Bukhari N, Rasheed H, Nayyer B, Babar ZUD. Pharmacists at the frontline beating the COVID-19 pandemic. J Pharm Policy Pract. 2020;13(1):8.
   PubMed Web of Science ®Google Scholar
• Ammar MA, Tran LJ, McGill B, Ammar AA, Huynh P, Amin N, et al. Pharmacists leadership in a medication shortage response: illustrative examples from a health system response to the COVID-19 crisis. J Am Coll Clin Pharm. 2021;4(9):1134–1143.
   PubMedGoogle Scholar
• Ministry of Health Malaysia. Garis Panduan Peluasan Penggunaan Rawatan Ubat Antiviral Covid-19 Bagi Fasiliti/Pengamal Perubatan Swasta. 2022. p. 28. https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX-2r-Garispanduan-Peluasan-Paxlovid-ke-Fasiliti-Swasta-25072022.pdf. Accessed 8 Sept 2022.
   Google Scholar
• Fact sheet for healthcare providers: emergency use authorization for paxlovid. 2022. p. 35. https://www.fda.gov/media/155050/download. Accessed 8 Sept 2022.
   Google Scholar
• Song Z, Hu Y, Zheng S, Yang L, Zhao R. Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: recommendations and guidance from clinical experience. Res Soc Adm Pharm. 2021;17(1):2027–2031.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Malaysia. Clinical management of confirmed covid-19 case in adult and paediatric. 2022. p. 29. https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX-2E-CLINICAL-MANAGEMENT-OF-CONFIRMED-COVID-19-31052022.pdf. Accessed 8 Sept 2022.
   Google Scholar
• Prioritization of therapeutics. COVID-19 treatment guidelines. 2022. https://www.covid19treatmentguidelines.nih.gov/overview/prioritization-of-therapeutics/. Accessed 11 Oct 2022.
   Google Scholar
• Infectious Diseases Society of America. Management of drug interactions with nirmatrelvir/ritonavir (Paxlovid®): resource for clinicians. 2022. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid. Accessed 9 Aug 2022.
   Google Scholar
• University of Liverpool. COVID-19 drug interactions. https://www.covid19-druginteractions.org/checker. Accessed 9 Aug 2022.
   Google Scholar
• Tanne JH. Covid-19: FDA authorises pharmacists to prescribe Paxlovid. BMJ. 2022;378:o1695.
   PubMedGoogle Scholar
• Grissinger M. The five rights: a destination without a map. Pharm Ther. 2010;35(10):1.
   Google Scholar
• Abbasi Nazari M, Salamzadeh J, Hajebi G, Gilbert B. The role of clinical pharmacists in educating nurses to reduce drug-food interactions (absorption phase) in hospitalized patients. Iran J Pharm Res. 2011;10(1):173–177.
   PubMed Web of Science ®Google Scholar
• Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine. 2016;95(15):e3361.
   PubMed Web of Science ®Google Scholar
• Sanii Y, Torkamandi H, Gholami K, Hadavand N, Javadi M. Role of pharmacist counseling in pharmacotherapy quality improvement. J Res Pharm Pract. 2016;5(2):132.
   PubMed Web of Science ®Google Scholar
• Bragazzi N, Mansour M, Bonsignore A, Ciliberti R. The role of hospital and community pharmacists in the management of COVID-19: towards an expanded definition of the roles, responsibilities, and duties of the pharmacist. Pharmacy. 2020;8(3):140.
   Web of Science ®Google Scholar
• Ritonavir-Boosted Nirmatrelvir (Paxlovid). COVID-19 treatment guidelines. 2022. https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/. Accessed 11 Oct 2022.
   Google Scholar
• Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006;166(5):565.
   PubMedGoogle Scholar
• Hadi MA, Neoh CF, Zin RM, Elrggal M, Cheema E. Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting. IPRP. 2017;6:91–98.
   Google Scholar
• Mei CS. Nirmatrelvir/Ritonavir (PAXLOVID): risk of anaphylaxis and hypersensitivity reactions. 2022. https://www.npra.gov.my/index.php/en/health-professionals/recent-updates/435-english/safety-alerts-main/safety-alerts-2022/1527403-nirmatrelvir-ritonavir-paxlovidtm-risk-of-anaphylaxis-and-hypersensitivity.html. Accessed 11 Oct 2022.
   Google Scholar
• European medicines Agency. Paxlovid for the treatment of Covid-19. 2021. p. 131. https://www.ema.europa.eu/en/documents/referral/paxlovid-pf-07321332-ritonavir-covid-19-article-53-procedure-assessment-report_en.pdf. Accessed 8 Sept 2022.
   Google Scholar
• Lee KK, Yang J, Hernandez AF, Steimle AE, Go AS. Post-discharge follow-up characteristics associated with 30-day readmission after heart failure hospitalization. Med Care. 2016;54(4):365–372.
   PubMed Web of Science ®Google Scholar
• National Pharmaceutical Regulatory Agency. Adverse Drug Reaction (ADR)/Adverse Event Following Immunisation (AEFI) reporting. 2021. p. 41. https://www.npra.gov.my/easyarticles/images/users/1047/Adverse-Drug-Reaction-ADR--Adverse-Event-Following-Immunisation-AEFI-Reporting-Manual-For-Healthcare-Providers.pdf. Accessed 8 Sept 2022.
   Google Scholar
• Adams SL, Thompson DA. Inability to follow up ED patients by telephone: there must be 50 ways to leave your number. Acad Emerg Med. 1996;3(3):271–273.
   PubMed Web of Science ®Google Scholar
• Ministry of Health Malaysia. Protease inhibitors (paxlovid®)—oral treatment for covid-19. 2021. p. 4. https://covid-19.moh.gov.my/kajian-dan-penyelidikan/mahtas-covid-19-rapid-evidence-updates/Rapid-Review-Paxlovid-Oral-treatment-for-covid-19-04022022.pdf. Accessed 8 Sept 2022.
   Google Scholar
• Elbeddini A, Yeats A. Pharmacist intervention amid the coronavirus disease 2019 (COVID-19) pandemic: from direct patient care to telemedicine. J Pharm Policy Pract. 2020;13(1):23.
   PubMed Web of Science ®Google Scholar
• Houser SH, Ray MN, Maisiak R, Panjamapirom A, Willig J, Schiff GD, et al. Telephone follow-up in primary care: can interactive voice response calls work? Stud Health Technol Inform. 2013;192:112–116.
   PubMedGoogle Scholar
• Agency for Healthcare Research and Quality. Tool 5: how to conduct a postdischarge follow-up phone call. 2013. https://www.ahrq.gov/patient-safety/settings/hospital/red/toolkit/redtool5.html. Accessed 9 Aug 2022.
   Google Scholar
• Sevelius JM, Gutierrez-Mock L, Zamudio-Haas S, McCree B, Ngo A, Jackson A, et al. Research with marginalized communities: challenges to continuity during the COVID-19 pandemic. AIDS Behav. 2020;24(7):2009–2012.
   PubMed Web of Science ®Google Scholar
• Nungsari M, Yin CH, Fong N, Pillai V. Understanding the impact of the COVID-19 outbreak on vulnerable populations in Malaysia through an ethical lens: a study of non-state actors involved in aid distribution. Wellcome Open Research; 2022. https://wellcomeopenresearch.org/articles/6-263. Accessed 11 Oct 2022.
   Google Scholar
• Chung MHL, Hazmi H, Cheah WL. Role performance of community health volunteers and its associated factors in Kuching District, Sarawak. J Environ Public Health. 2017;2017:9610928.
   PubMedGoogle Scholar
• Haase J, Farris KB, Dorsch MP. Mobile applications to improve medication adherence. Telemed e-Health. 2017;23(2):75–79.
   PubMed Web of Science ®Google Scholar
• Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD012675.
   Web of Science ®Google Scholar
• John Leon Singh H, Couch D, Yap K. Mobile health apps that help with COVID-19 management: scoping review. JMIR Nurs. 2020;3(1):e20596.
   PubMedGoogle Scholar
• Tursunbayeva A, Renkema M. Artificial intelligence in health-care: implications for the job design of healthcare professionals. Asia Pac J Hum Res. 2022. https://doi.org/10.1111/1744-7941.12325.
   Web of Science ®Google Scholar
• Ortega A, Aguinagalde A, Lacasa C, Aquerreta I, Fernández-Benítez M, Fernández LM. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. Ann Pharmacother. 2008;42(10):1491–1496.
   PubMed Web of Science ®Google Scholar